Evidence map›Paper›PMID 40260502›Full record

ArticleJournal of cell science2025

Abnormal nucleoli architecture and aggregate formation in nucleophosmin mutated acute myeloid leukaemia.

Martin Grundy, Kellie Lucken, Xiaomeng Xing, Eva L Simpson, Alice Worker, Ahmed Bayyoomi, Alison J Beckett, Ian A Prior, Daniel G Booth, Claire H Seedhouse

Abstract read
In one paragraph

Article in Journal of cell science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Martin GrundyTranslational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, United Kingdom.ORCID 0000-0002-0719-2469
Kellie LuckenTranslational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, United Kingdom.ORCID 0000-0001-6175-7697
Xiaomeng XingTranslational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, United Kingdom.
Eva L SimpsonTranslational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, United Kingdom.
Alice WorkerTranslational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, United Kingdom.
Ahmed BayyoomiTranslational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, United Kingdom.ORCID 0009-0007-2749-0758
Alison J BeckettMolecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 7BE, UK.
Ian A PriorMolecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 7BE, UK.
Daniel G BoothTranslational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, United Kingdom.ORCID 0000-0001-6216-2863
Claire H SeedhouseTranslational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, United Kingdom.ORCID 0000-0003-2280-4045

Funding

Academy of Medical Sciences SBF006\1071Biotechnology and Biological Sciences Research Council BB/V005626/1Center for Pharmaceutical Research and Innovation, University of Kentucky BB/V005626/1Engineering and Physical Sciences Research Council EP/S021434/1Leverhulme Trust RPG-2021-118North West Cancer Research CR1166Nottingham Hospitals Charity FR-000000775/N0288Nottinghamshire Leukaemia AppealRoyal Society RGS/R2/202366UK Research and Innovation BB/V005626/1University of Nottingham
6 · The paper itself

Abstract

Mutations in the nucleophosmin (NPM1) gene represent the most common genetic alteration in acute myeloid leukaemia (AML) and result in mis-localisation of the mutated protein from a predominantly nucleolar localisation to a predominantly cytoplasmic distribution. Here, we use high resolution imaging to demonstrate that NPM1 is crucial for maintaining normal nucleoli architecture and specifically the integrity of the enigmatic nucleoli rim, the least understood nucleolar compartment. We demonstrate that cell lines and primary cells with NPM1 mutations from individuals with AML have aberrant nucleoli architecture; intriguingly this abnormal nucleolar phenotype is reversible. Using a surrogate for rRNA synthesis, we show that the aberrant phenotype is associated with differences in nucleolar function; specifically, activity of RNA polymerase I is increased in NPM1 mutated cells. Perinucleolar chromatin organisation is also markedly different in NPM1 mutant cells. Finally, we report the novel finding that NPM1 mutated protein forms distinct aggregates and characterise these for the first time. This work reveals how nucleolar organisation contributes to the molecular mechanisms underpinning NPM1-driven AML, revealing novel therapeutic vulnerabilities.

Indexed as

Cell NucleolusLeukemia, Myeloid, AcuteMutationNuclear ProteinsCell Line, TumorChromatinHumansNucleophosminRNA Polymerase IChromatinNPM1 protein, humanNuclear ProteinsNucleophosminRNA Polymerase IAcute myeloid leukaemiaAggregatesMutationsNucleoliNucleophosmin

Identifiers

PMID40260502
PMCPMC12148033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.